Anacor Pharma (ANAC) Tops Q2 EPS by 2c

Anacor Pharma (NASDAQ: ANAC) reported Q2 EPS of ($0.30), $0.02 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $17.8 million versus the consensus estimate of $18.75 million.

“2015 continues to be a very productive year for Anacor. We recently announced that crisaborole, our novel non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the potential treatment of mild-to-moderate atopic dermatitis in children and adults, achieved statistically significant results on all primary and secondary endpoints in two Phase 3 pivotal studies and demonstrated a safety profile consistent with previous studies. If approved, we believe crisaborole could offer an important treatment option for the many patients living with this serious skin disease, as well as the physicians who treat them,” said Paul L. Berns, Chairman and Chief Executive Officer of Anacor. “In addition, we are pleased with the recently announced amendment to the Sandoz Agreement. We believe the increased investment in KERYDIN commercial activities will help increase brand awareness among the patients suffering from onychomycosis who are most likely to use KERYDIN, and motivate them to seek treatment from their physicians.”

Cash, cash equivalents and investments totaled $176.9 million at June 30, 2015, compared to $191.6 million at December 31, 2014.

For earnings history and earnings-related data on Anacor Pharma (ANAC) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Movano (MOVE) Misses Q2 EPS by 195c
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15